Please login to the form below

Not currently logged in
Email:
Password:

Merck (MSD) expands South African business

Merck (MSD) has entered into a collaboration with Adcock Ingram to co-promote and distribute a number of products in the South African market

Merck (MSD) has entered into strategic collaboration deal with South African company Adcock Ingram. The two companies will co-promote and distribute a selection of prescription products across a number of therapy areas including: asthma, dermatology, hypercholesterolemia, hypertension, migraine and osteoporosis. A number of over-the-counter (OTC) products will also be included in the deal. All of the products are currently registered in South Africa by MSD and Schering-Plough.

Financial details of the deal were not disclosed.

Dr Stefan Oschmann, president, Emerging Markets, MSD said: "We expect sales from these [emerging] markets to be a key contributor to our future performance and growth. As part of our pursuit of that growth we will strive to expand our presence across emerging markets by actively seeking local collaborations." 

Merck expects more than 25 per cent of its global pharmaceutical and vaccine revenue in 2013 to come from emerging markets. The company is the second biggest pharmaceutical company (by revenue) in the world. Its key products include the cholesterol drugs Vytorin (ezetimibe and simvastatin) and Zetia (ezetimibe), and the asthma therapy Singulair (montelukast sodium).

Merck is known as MSD outside of the US and Canada.

24th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics